Tackling Infectious Diseases — House of Commons, 2017-04-20
Topic: International Affairs
Wendy Morton (Conservative, Centre-right): I congratulate the hon. Member for Ealing, Southall (Mr Sharma) on securing the debate, along with two other members of the International Development Committee. As always, it is a pleasure to follow my hon. Friend the Member for Stafford (Jeremy Lefroy), who always speaks from great experience and with great knowledge of neglected tropical diseases. I know that he has done a huge amount of work on tackling malaria Today’s debate is timely. Last week, DFID announced a doubling of its support for the fight against neglected tropical diseases such as trachoma, Guinea worm and river blindness over the next five years. It was also announced that the UK would invest £360 million in programmes to tackle this type of disease. This week, the World Health Organisation is hosting a summit on neglected tropical diseases, and we have seen the coming together of Governments, non-governmental organisations, multilateral organisations, the private sector, and the Bill and Melinda Gates Foundation, which many Members have mentioned. That highlights the importance of tackling those terrible diseases that strike at the heart of some of the most vulnerable people in the world As a member of the International Development Committee and a co-chair of the all-party parliamentary group on the United Nations global goals for sustainable development, I wanted to speak in what will be perhaps the last international development debate in this Parliament and to take the opportunity to highlight some of the incredible work that UK aid has delivered. I am sure that the Minister will tell us more about the Department’s record over the past few years The UK is investing in research and development for new technologies to fight neglected tropical diseases with funding from the Ross fund, which is a £1 billion fund aimed at developing, testing and producing new products—particularly for malaria. We often hear of the importance of bed nets in the tackling of malaria, but that is not the only answer to the problem; we also need to look at drugs, insecticides and diagnostics. The importance of working to tackle antimicrobial resistance has also been mentioned We must not forget the impact of Ebola in recent years—a topic that the Committee has done an inquiry on. It is a terrible infectious disease that affected people not only in Sierra Leone and Africa; we know of a couple of British citizens who were seriously affected by it as well. That highlighted the importance not only of looking for ways of testing for the disease and curing it, but of having adequate healthcare systems Tackling neglected tropical diseases is clearly good news for those countries that are most badly affected by them. It is also good news for our universities, pharma companies and many of our NGOs and charities; they have vital roles to play in this, too. That also keeps us as British citizens safe. Many of us travel around the world, so it is important for our safe and secure passage to seek protection from and find solutions to those diseases I have mentioned Ebola and malaria, and the Zika virus is another infectious disease; we do not hear about many diseases until there is an epidemic or a really serious outbreak. To me, it also illustrates why the UK aid budget really matters. When we spend it wisely, it can make a difference to people’s lives—and it is in our interests to do that. We know that infectious diseases disproportionately affect the poorest people, exacerbate instability and put at risk our national security Last year, the UN high-level panel on access to medicines made a number of recommendations aimed at getting more medicines to more people who need them. It also recognised that research and development alone is not enough. Intellectual property law, competition law, procurement laws, drug regulations, public health obligations and patents are all part of this, as is price, which can be a major barrier to accessing treatment globally. For example, generic competition in antiretroviral medicines has led to the cost of first-line ARV drugs decreasing, but third-line ARVs remain prohibitively expensive—especially in middle-income countries. To make that even more pressing, by 2020 an estimated 70% of people living with HIV will be in middle-income countries Britain has a proud record in this field. We are leading the way in fighting these diseases through research, targeting and tackling the real root causes of avoidable infections and diseases. However, while we have achieved so much, as usual it is the case that much more can be done. I hope that the Minister will set out his Department’s plans. We know that he is committed to this area. As I began by saying, I welcome the work that DFID has done.